2-Morpholin-4-ylethyl 2-(1-benzyl-2-methyl-3-oxamoylindol-4-yl)oxyacetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Morpholin-4-ylethyl 2-(1-benzyl-2-methyl-3-oxamoylindol-4-yl)oxyacetate
• 化学式: C₂₆H₂₉N₃O₆
• 分子量: 479.5
• InChiKey: SVTSSTMPGWZTHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
  申请人：Chang Han-Ting

  公开号：US20070135385A1

  公开（公告）日：2007-06-14

  Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.

  吲哚和与吲哚相关的化合物、组合物以及方法被披露。发明中的这些化合物作为磷脂酶抑制剂非常有用。发明中的这些化合物和组合物用于治疗动物受试者中的磷脂酶相关状况，例如胰岛素相关、体重相关和/或胆固醇相关状况。
• Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds
  申请人：Buysse M. Jerry

  公开号：US20080021049A1

  公开（公告）日：2008-01-24

  The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a phospholipase A2 inhibitor having comprising a substituted organic compound having a fused five-member ring and six-member ring, such as indole-containing compounds.

  本发明提供了治疗磷脂酶相关疾病的方法和组合物。特别地，本发明提供了一种治疗动物主体中的胰岛素相关、体重相关和/或胆固醇相关疾病的方法。该方法通常涉及到给动物主体注射一种含有融合的五元环和六元环的取代有机化合物的磷脂酶A2抑制剂，例如吲哚类化合物。
• Phospholipase Inhibitors Localized in the Gastrointestinal Lumen
  申请人：Charmot Dominique

  公开号：US20070292385A1

  公开（公告）日：2007-12-20

  The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.
• Treatment Of Hypercholesterolemia, Hypertriglyceridemia And Cardiovascular-Related Conditions Using Phospholipase-A2 Inhibitors
  申请人：Charmot Dominique

  公开号：US20080051447A1

  公开（公告）日：2008-02-28

  The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.
• USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS
  申请人：Trias Joaquim

  公开号：US20090062369A1

  公开（公告）日：2009-03-05

  Administration of sPLA 2 inhibitors has been found to decrease sPLA 2 levels in human serum. Provided herein are methods of decreasing serum sPLA 2 levels in a subject in need thereof, as well as methods for accurately measuring sPLA 2 levels in a serum sample.